ABSCI CORP Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
ABSCI CORP (ABSI) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period of 59.62 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod · last filed 2026-08-11
- ABSCI CORP share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2026-06-30 was 12.39K shares, a 96.78% decline year-over-year.
- ABSCI CORP share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2026-03-31 was 47.23K shares, a 63.43% decline year-over-year.
- ABSCI CORP share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-12-31 was 334.24K shares, a 1084.57% increase year-over-year.
- ABSCI CORP share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-09-30 was 112.30K shares, a 15.27% decline year-over-year.
- ABSCI CORP share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2025 was 960.32K shares, a 338.91% increase from fiscal 2024.
- ABSCI CORP share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2024 was 218.80K shares, a 71.73% decline from fiscal 2023.
- ABSCI CORP share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2023 was 773.86K shares, a 178.72% increase from fiscal 2022.
- ABSCI CORP share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2022 was 277.65K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 12.39K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | 59.62K shares 10-Q · filed 2026-08-11 | 393.86K shares derived: sum of 3 quarters · filed 2026-08-11 | 506.16K shares derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | 47.23K shares 10-Q · filed 2026-05-07 | 381.47K shares derived: sum of 2 quarters · filed 2026-05-07 | 493.77K shares derived: sum of 3 quarters · filed 2026-05-07 | 878.40K shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | 334.24K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | 446.54K shares derived: sum of 2 quarters · filed 2026-03-24 | 831.17K shares derived: sum of 3 quarters · filed 2026-03-24 | 960.32K shares 10-K · filed 2026-03-24 |
| 2025-09-30 | 112.30K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | 496.93K shares derived: sum of 2 quarters · filed 2025-11-12 | 626.08K shares 10-Q · filed 2025-11-12 | 654.30K shares derived: sum of 4 quarters · filed 2025-11-12 |
| 2025-06-30 | 384.63K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | 513.78K shares 10-Q · filed 2025-08-12 | 542.00K shares derived: sum of 3 quarters · filed 2025-08-12 | 674.54K shares derived: sum of 4 quarters · filed 2025-08-12 |
| 2025-03-31 | 129.15K shares 10-Q · filed 2025-05-13 | 157.37K shares derived: sum of 2 quarters · filed 2025-05-13 | 289.91K shares derived: sum of 3 quarters · filed 2025-05-13 | 307.86K shares derived: sum of 4 quarters · filed 2025-05-13 |
| 2024-12-31 | 28.22K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | 160.76K shares derived: sum of 2 quarters · filed 2025-03-18 | 178.71K shares derived: sum of 3 quarters · filed 2025-03-18 | 218.80K shares 10-K · filed 2025-03-18 |
| 2024-09-30 | 132.55K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | 150.49K shares derived: sum of 2 quarters · filed 2024-11-12 | 190.58K shares 10-Q · filed 2024-11-12 | 590.97K shares derived: sum of 4 quarters · filed 2024-11-12 |
| 2024-06-30 | 17.95K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | 58.03K shares 10-Q · filed 2024-08-14 | 458.43K shares derived: sum of 3 quarters · filed 2024-08-14 | 739.96K shares derived: sum of 4 quarters · filed 2024-08-14 |
| 2024-03-31 | 40.09K shares 10-Q · filed 2024-05-14 | 440.48K shares derived: sum of 2 quarters · filed 2024-05-14 | 722.01K shares derived: sum of 3 quarters · filed 2024-05-14 | 753.68K shares derived: sum of 4 quarters · filed 2024-05-14 |
| 2023-12-31 | 400.39K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | 681.92K shares derived: sum of 2 quarters · filed 2024-03-21 | 713.59K shares derived: sum of 3 quarters · filed 2024-03-21 | 773.86K shares 10-K · filed 2024-03-21 |
| 2023-09-30 | 281.54K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | 313.20K shares derived: sum of 2 quarters · filed 2023-11-14 | 373.47K shares 10-Q · filed 2023-11-14 | 631.45K shares derived: sum of 4 quarters · filed 2023-11-14 |
| 2023-06-30 | 31.67K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | 91.94K shares 10-Q · filed 2023-08-14 | 349.92K shares derived: sum of 3 quarters · filed 2023-08-14 | 359.84K shares derived: sum of 4 quarters · filed 2023-08-14 |
| 2023-03-31 | 60.27K shares 10-Q · filed 2023-05-15 | 318.25K shares derived: sum of 2 quarters · filed 2023-05-15 | 328.18K shares derived: sum of 3 quarters · filed 2023-05-15 | 328.92K shares derived: sum of 4 quarters · filed 2023-05-15 |
| 2022-12-31 | 257.98K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | 267.90K shares derived: sum of 2 quarters · filed 2023-03-30 | 268.65K shares derived: sum of 3 quarters · filed 2023-03-30 | 277.65K shares 10-K · filed 2023-03-30 |
| 2022-09-30 | 9.92K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | 10.67K shares derived: sum of 2 quarters · filed 2022-11-09 | 19.67K shares 10-Q · filed 2022-11-09 | |
| 2022-06-30 | 742.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | 9.75K shares 10-Q · filed 2022-08-11 | ||
| 2022-03-31 | 9.01K shares 10-Q · filed 2022-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |